Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Long-Term Investments of $8.8 million for Q3 2025, down 49.6% year-over-year from $17.5 million in Q3 2024, and down 12.46% quarter-over-quarter from $10.1 million in Q2 2025.
Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2026) Analysis & Trends
Sagimet Biosciences' Long-Term Investments history runs 2 years deep, the most recent figure standing at $8.8 million for Q3 2025.
- In Q3 2025, Long-Term Investments fell 49.6% year-over-year to $8.8 million; the TTM figure through Sep 2025 stood at $8.8 million (down 49.6% YoY), while the FY2024 annual figure was $7.4 million, changed N/A from the prior year.
- Long-Term Investments for Q3 2025 stood at $8.8 million, down from $10.1 million in the prior quarter.
- The five-year high for Long-Term Investments was $22.1 million in Q2 2024, with the low at $7.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 17.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.44 Mn |
| Sep 30, 2025 | 8.81 Mn |
| Jun 30, 2025 | 10.06 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 17.47 Mn |
| Jun 30, 2024 | 22.12 Mn |